Nicotine reduces effectiveness of doxorubicin chemotherapy and promotes CD44<sup>+</sup>CD24<sup>−</sup> cancer stem cells in MCF-7 cell populations

LELYA TÜRKER ŞENER<sup>1</sup>, CELAL GÜVEN<sup>2</sup>, AZIZ ŞENER<sup>3</sup>, SUZAN ADIN ÇINAR<sup>4</sup>, SEYHUN SOLAKOĞLU<sup>5</sup> and İŞIL ALBENIZ<sup>1</sup>

<sup>1</sup>Department of Biophysics, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul;  
<sup>2</sup>Department of Biophysics, Faculty of Medicine, Niğde Ömer Halisdemir, 02040 Niğde;  
<sup>3</sup>Department of General Surgery, Kanuni Sultan Suleyman Training and Research Hospital, 34306 Istanbul;  
<sup>4</sup>Department of Immunology, Institute of Experimental Medicine;  
<sup>5</sup>Department of Histology and Embryology, Istanbul Faculty of Medicine, Istanbul University, 34093 Istanbul, Turkey

Received February 27, 2017; Accepted June 5, 2017

DOI: 10.3892/etm.2018.6149

Abstract. Breast cancer is the most common type of cancer in females and the second most common cause of cancer mortality after lung cancer. Cancer stem cells represent a novel approach to target cancer and reduce cancer recurrence and metastasis. Many patients with breast cancer continue to smoke after receiving their diagnosis. Nicotine is a key factor in tobacco addiction and also changes some cellular functions, such as activation of mitogenic pathways, angiogenesis and cell proliferation. In the present study, the impact of nicotine was assessed in a population of MCF-7 human breast cancer cells. Cluster of differentiation (CD)44<sup>+</sup>CD24<sup>−</sup> cancer stem cell population of MCF-7 cells were evaluated using flow cytometry and scanning electron microscopy. Chemoresistance effects of nicotine were demonstrated in these cells. These findings demonstrated harmful effects of nicotine following metastasis of cancer, owing to the chemoresistance produced through uninterrupted smoking, which may impact the effectiveness of treatment.

Introduction

Breast cancer has a high incidence and poses a notable threat to human health, particularly in females (1). The worldwide recurrence and metastasis rate in patients with early breast cancer is estimated to be ~30% (1). Breast cancer metastasizes to the lungs, bone, liver and brain (2). Metastasis is a complex process that relies to a great extent on the interaction between primary tumors and the tumor-associated host stromal tissue (2). Surgical procedures, radiation-, endocrine- and/or chemotherapy are required for the treatment of the disease (3).

A frequently used chemotherapeutic drug in breast cancer is doxorubicin, which inhibits the replication of DNA by intercalating into and inhibiting the enzyme topoisomerase II. In doing so, the cell cycle stops and the cancerous cells undergo apoptosis (4). However, some types of breast cancer are known to develop resistance to anticancer agents such as doxorubicin (5). An increased risk of breast cancer development has been associated with cigarette smoking in epidemiological and clinical studies in which smokers and non-smokers were compared (5-7). Of the 4,000 components in cigarette smoke, the most important and effective is known to be nicotine (2) for breast cancer.

Long-term smoking of tobacco clinically contributes to the development of cardiovascular disease and also to the development of cancer (8). While smoking, 80-90% of inhaled nicotine (~1.0 mg per cigarette) is systemically absorbed (9). Nicotine is thought to have a role in the formation of various types of cancer and has been demonstrated to increase angiogenesis in previous proliferation model studies (10-15).

Cancer stem cells (CSCs) have become an important topic in oncology research. Malignant cancer stem cells were first identified and isolated from solid breast cancer tumor (16). Human cell surface antigen, cluster of differentiation (CD24), is a marker for normal mammary stem cells; however, when combined with other markers, CD24<sup>+</sup> breast cancer cells have the greatest tumor-initiating potential and may be successfully identified in stem cell populations (17).

Breast cancer stem cells are different from other breast cancer cells with regards to volume, size, membrane components, antigen expression, proliferation and metastasis (18). In the cancer stem cell model, a small group of tumor cells are responsible for cancer formation, progression and recurrence (11). A study by Honeth et al determined that the CD24 and CD44 cell surface proteins are putative markers for cancer stem cell populations in breast cancer (18).

In a previous study, breast CSCs were enriched in the minority fraction of CD44<sup>+</sup>CD24<sup>−</sup> lineage cells, with as few as 100 CD44<sup>+</sup>CD24<sup>−</sup> cells able to initiate tumor growth...
in immunocompromised mice (19). A study by Al Hajj et al. was the first to isolate CSCs from human breast cancer. They prospectively identified and isolated the tumorigenic cells as CD44(+)/CD24(-/low) lineage (-) in 8/9 patients. CSCs are hypothesized to be a subset of tumor cells with stem cell-like features that have the ability to self-renew and differentiate, which causes a heterogeneous tumor cell population (20). This variability led to diverse results in clinical studies (21). Previous studies reported that CD44+/CD24-breast CSCs enhance breast tumor cells because of their angiogenic potential (20-25).

The effects of daily exposure to chemical agents may be determined at a cellular level with advanced imaging techniques, including positron-emission tomography (26). These analyses of cancer cells and biotechnological advances are opening new horizons of molecular oncology and also provide major advances in our understanding of oncology.

Breast cancer is managed through surgical treatment, radiation therapy, endocrine therapy and/or chemotherapy (21). Resistance to chemotherapy is a challenge for the successful cure of several types of cancer; breast cancer has evolved resistance to a number of anticancer agents, such as doxorubicin (23,24). There is limited experimental data that supports direct links between breast cancer and exposure to nicotine. The present findings demonstrated the harmful effects of nicotine following metastasis of cancer due to the chemoresistance produced through uninterrupted smoking, which may impact the effectiveness of treatment.

**Materials and methods**

**Cell culture and treatment.** The human breast cancer cell line MCF-7 (American Type Culture Collection, Manassas, VA, USA) used in the present study was grown in Dulbecco's modified Eagle's medium (DMEM; Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; PAA Laboratories; GE Healthcare, Chicago, IL, USA), 2 mM glutamine, 10 U/ml penicillin and 100 µg/ml streptomycin (all Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). The cells were cultured in a humidified incubator with a 37°C in an atmosphere containing 5% CO₂.

For nicotine treatment, cells were washed twice with phosphate-buffered saline (PBS), dissociated with 0.25% trypsin (Gibco; Thermo Fisher Scientific, Inc.) and seeded near confluence (2x10⁵ cells/well) in 6-well plates. Cells were cultured in complete medium at 37°C in a 5% CO₂ incubator for 24 h prior to nicotine treatment (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). The cells were collected in a humidified incubator with a 37°C in an atmosphere containing 5% CO₂.

For nicotine treatment, cells were plated onto poly-D-lysine-coated 6-well glass chamber slides (7000 cells/well) and incubated at 37°C in a 5% CO₂ incubator for 24 h. After 24 h incubation, cells were treated with 0.01, 0.05, 0.1, 1 or 10 µM nicotine for the indicated time points (24 and 48 h).

**Cell diameter.** MCF-7 cells were analyzed with a Vi-Cell XR cell viability analyzer (Beckman Coulter, Inc., Brea, CA, USA). MCF-7 cell diameters were measured 24 and 48 h after treatment with nicotine using the Vi-Cell XR cell viability analyzer.

**Scanning electron microscopy (SEM).** MCF-7 cells were plated on 6-well plates (7x10⁶ cells/well). The cells were cultured in DMEM (Clonetics; Lonza Group, Ltd., Basel, Switzerland), which consisted of 5% FBS, 0.1% penicillin strept. MCF-7 breast cancer cells were centrifuged at 1600 x g. Cells were collected and prepared in accordance with the method of Groebel et al (27) and analyzed using an FEI Quanta 450 FEG-EDS scanning electron microscope (Thermo Fisher Scientific, Inc.).

**Transmission electron microscopy (TEM).** MCF-7 breast cancer cells were centrifuged at 1600 x g, 5 min at room temperature after treatment trypsin-EDTA. Cells were collected and prepared in accordance with the method of Groebel et al (27) and analyzed using a Philips CM100 transmission electron microscope (Philips Medical Systems, Inc., Bothell, WA, USA).

**CSC analysis by flow cytometry.** Allophycocyanin (APC)-conjugated mouse anti-human CD44 monoclonal antibody (cat. no. BD 559942) and phycoerythrin/cyanine 7 (PE/Cy7)-conjugated mouse anti-human CD24 monoclonal antibody (cat. no. BD 561646) were purchased from BD Pharmingen (BD Biosciences, Franklin Lakes, NJ, USA). CD24 and CD44 expression was analyzed in cells derived from monolayer cultures following dissociation in trypsin-EDTA at 37°C. At least 1x10⁶ cells were pelleted by centrifugation at 500 x g for 5 min at 4°C. Cells were washed in PBS, resuspended with anti-CD24-PE/Cy7 (1:20 dilution) and anti-CD44-APC (1:20 dilution); samples were incubated for 30 min at 4°C in the dark. The labeled cells were washed using PBS and analyzed using a BD FACSAria II flow cytometer and software DiVa (BD Biosciences). The negative fraction was determined using appropriate isotype controls.

**Actin immunostaining.** MCF-7 breast cancer cells were plated onto poly-D-lysine-coated 6-well glass chamber slides (7000 cells/well) and incubated at 37°C in a 5% CO₂ incubator for immunostaining. After 24 h incubation, cells were treated with 0.01, 0.05, 0.1, 1 or 10 µM nicotine for the indicated time points (24 and 48 h). Immunofluorescence microscopy was used to determine F-actin organization in MCF-7 breast cancer cells. The cells were fixed in 3.5% paraformaldehyde in PBS for 10 min at room temperature. Cells were permeabilized and blocked in PBS containing 0.1% Triton X-100 and 5% FBS for 30 min at room temperature. Actin filaments were visualized using rhodamine-phalloidin label, and nuclei were stained with DAPI (Invitrogen; Thermo Fisher Scientific, Inc.). All images were obtained using an Olympus BX51 Microscope equipped with a DP72 camera, controlled by Olympus DP2-TWAIN software (ver7.2; Olympus Corp., Tokyo, Japan) (28).

**Doxorubicin resistance.** A final doxorubicin (Sigma-Aldrich; Merck KGaA) concentration of 2.5 µg/ml was used in the present study. Cells were divided into a total of six groups (doxorubicin concentrations were 0.5, 1, 2, 4 or 8 µM) and in the control group MCF-7 cells received no treatment with doxorubicin. MCF-7 breast cancer cells were shaken every 15-20 min during their incubation with doxorubicin at 37°C for 1 h. The cell viability test was performed using trypan blue (29).

**Statistical analysis.** Statistical analysis was performed and data were presented as the mean ± standard deviation, For
comparisons of two normally distributed groups, a Student t-test was used. All statistical analysis was performed using SPSS software for Windows (version 21; IBM Corp., Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Effect of nicotine on actin cytoskeleton in MCF-7 breast cancer cells. Lamellipodia formation on filamentous actin was investigated using fluorescence microscopy, in order to evaluate whether nicotine increases the metastatic potential in breast cancer (Fig. 1). MCF-7 cells appeared to have a diamond or polygonal shape. The F-actin filaments of the MCF-7 breast cancer cells treated with nicotine were altered to a rounded form with a smaller diameter. This effect was more pronounced as the concentration and duration of nicotine treatment increased.

Effect of nicotine on cellular surface morphology and ultrastructure. The surfaces of the nicotine treated MCF-7 cells (grown in DMEM with 5% FBS) as viewed under SEM were almost uniformly covered with an increased dense network of microvilli (Fig. 2A), whereas nicotine-treated cells typically exhibited an increase in the density and length of surface microvilli (Fig. 2). The SEM results supported our hypothesis in which an elevated number of filopodia were identified with a higher extensively in the nicotine-treated groups.

Nicotine increases the CD44⁺CD24⁻ cell population in MCF-7 cells. To investigate whether nicotine affects the size of a CSC population, MCF-7 human breast cancer cells were characterized using flow cytometry for surface expression of CD44 and CD24, which is used for the identification of CSCs. As demonstrated in Fig. 3, stimulation with 0.01, 0.05, 0.1, 1 or 10 µM nicotine increased the ratio of CSCs. Treatment with 1 µM nicotine after 24 h, increased CD44⁺CD24⁻ cells (~1.6-fold), suggesting that the effect of nicotine is due to the proliferation of CD24⁻ cells. As demonstrated in Fig. 3, the effect of nicotine was observed in a dose-dependent manner until 1 µM nicotine treatment, after which the cell population was decreased at 10 µM, which indicated that maximal effects were achieved at a concentration of 1 µM. To confirm whether nicotine increases the CSC population, expression patterns of CD24 and CD44 in MCF-7 cells were analyzed by flow cytometry were determined. The results suggested that nicotine increased the proportion of CSCs in the cell population (Fig. 3B). Smaller changes between 24 and 48 h in cell diameter measurements were observed in nicotine-treated groups compared with controls (Fig. 4).

Nicotine treatment promotes cell viability during doxorubicin exposure. It would be beneficial to determine the specific compounds within cigarettes that may be responsible for promoting drug resistance because cigarettes contain a mixture of compounds. Therefore, the present study aimed to determine whether nicotine, a specific component of cigarettes, may be responsible for chemotherapy drug resistance. Trypan blue cell counting was performed to compare survival curves between control cells and 1 µM nicotine-treated cells in the presence of increasing doxorubicin concentrations (Fig. 5). The results demonstrated that nicotine significantly increased MCF-7 cell viability during exposure to 0.5, 2, 4 or 8 µM doxorubicin (P<0.01).
Discussion

Nicotine and its derivatives are well documented for their role in addiction and wide range of effects in cancer. Nicotine stimulates the cellular and molecular pathways in carcinogenesis throughout the gastrointestinal tract (28). Furthermore, nicotine affects the function of numerous systems in the human body (28). Nicotine is an established cause of numerous...
In vivo studies have provided evidence of direct actions of nicotine, known as the dependency-inducing ingredient of cigarettes, regarding tumor development by increasing the risk of cancer types (10-13); however, its role in breast cancer etiology is unclear. In the present study, the potential effects of nicotine in human breast cancer cells were evaluated.

Figure 3. Effect of various concentrations of nicotine on CD44+/CD24- cell population. (A) Percentage of stem cells (CD44+/CD24-) in the MCF-7 cell population was determined by flow cytometry analysis. (B) Expression patterns of CD24 and CD44 in MCF-7 cells were analyzed by flow cytometry for 24 and 48 h. Anti-CD24 antibody labeled with PE-Cy7 and anti-CD44 antibody labeled with APC were applied to the analysis. Gates are based on the isotype control corresponding to each cell line. PE-Cy7, phycoerythrin-cyanine 7; APC, allophycocyanin; CD, cluster of differentiation.

Figure 4. Effects of nicotine treatment on diameter. Average diameter of MCF-7 cells 48 h following the application of nicotine. Cell diameter of MCF-7 was significantly decreased compared with untreated cells after 24 and 48 h exposure at 1-10 µM nicotine. *P<0.05 as compared to the control group (0 µM nicotine).

Figure 5. Effect of nicotine on the viability of MCF-7 cells during doxorubicin exposure. *P<0.01 vs. control (0 µM nicotine).
cell proliferation and interfering with apoptosis (13-15). It is known that, aside from tumor development, nicotine also causes changes in the human immune system (30-33). Heeschen et al (13) has demonstrated proliferation, membrane transport, metabolic and hormonal changes in nicotine induced cells.

Nicotine in plasma was previously reported to be between 10 nM and 10 µM in smokers (33). Therefore, in the present study, these nicotine concentrations were used in accordance with previous reports. Nicotine is taken into the body by chewing nicotine gum, by sniffing tobacco or sucking it into the mouth through the use of cigarettes. Plasma concentrations of nicotine rise slowly, reach a peak level after 30 min and do not fall during the following 2 h (34). In nicotine gums, nicotine is secreted as the gum is chewed, therefore a complete extraction of nicotine from the gum does not occur (2 mg gum provides 53% secretion, while 4 mg gum ensures 72% secretion). In this circumstance, a significant amount of nicotine is swallowed through the mouth (34,35).

A previous study indicated that it took 15-30 min for 4-mg gum to raise the plasma nicotine by an average of 9-11 ng/ml compared with an average increase of 8-27 ng/ml within 2 min of completing each cigarette (36). Furthermore, nicotine is believed to be responsible for the occurrence and development of several cancer types, including breast cancer (37). Previous study models have also demonstrated that nicotine increases angiogenesis and proliferation (38).

In the present study, when the results of the 24- and 48-h analyses of MCF-7 cells on an XR viability analyzer were evaluated between themselves, a nicotine dose-dependent increase in cell diameter was observed some changes in cell diameter measurements in the cells treated with nicotine compared with the controls. Cells were suspended with trypsin/EDTA during the sphere shape conducted using the cell XR viability analyzer.

CSCs, or tumor-initiating cells, have a major role in the onset of cancer and they have a resistance against chemotherapy and radiotherapy (39,40). In the present study, the presence of nicotine, these cells increase in number and invade, induced by changes in the dynamic values of other cells, thus providing mobility. This suggests that treatment would be hindered by nicotine intake, thereby deteriorating the treatment process. There is an increasing amount of evidence that suggests that breast cancer stem cells have a central role in the development of cancer (38). A clinical study has indicated that breast cancer metastases occur in the lungs of smokers (40). The findings of the present study suggested that in the presence of nicotine, the number of CSCs is associated with an increase in the CD24- cell population, which is active in metastasis. Like alcohol, nicotine is a facilitating risk factor in the metastasis process of breast cancer (38).

An investigation of the microcirculation of mammals has indicated that nicotine results in cell proliferation, membrane transport, metabolic and hormonal changes (41). The results of the present study are consistent with these suggestions. Gradually increasing dosages of nicotine, which were within the limits of nicotine in the blood plasma of smokers, stimulated the number of MCF-7 cancer stem cells. It was identified that 1 µM nicotine increased the number of CD44+CD24- cells among the MCF-7 cells. The decrease in viability and ratio of CD44+CD24- cells following treatment with 10 µM nicotine may be explained by a possible toxic effect.

Stimulation with nicotine may be the result of the increase in the percentage of CD24-MCF-7 cells, as identified by flow cytometry. Furthermore, the effects of nicotine on a CSC population were investigated with flow cytometry based on the CD44+CD24- characteristics, and it was found that it also stimulates CSC proliferation. This finding suggested a direct relation of nicotine with disease development and progression in patients with breast cancer who smoke.

Cell morphology findings of the present study demonstrated that nicotine increased cell invasion, although the results with electron microscopy and florescent microscopy indicated the orientation of cells but did not provide quantitative information about the invasive ability of breast cancer cells without characteristics of CSCs. Flow cytometry results suggested that nicotine had a proliferation-inducing effect on the CD44+CD24- cell population. This difference was not observed in all cells in the study areas but it was identified in higher numbers in the nicotine groups. This may be explained by the heterogeneous quality of the population. Previous research has demonstrated the effects of nicotine on cell morphology, motility and the cytoskeleton, which leads to degradation of the actin cytoskeleton and finally to cell destruction (42,43).

In the present study, re-characterization of F-actin, a basic cortical skeletal component of in vitro cancer models, was also identified to be among the potential effects of nicotine on breast cancer cells. Nicotine-administered MCF-7 breast cancer cells exhibited changes in cell structure, including becoming rounder in form with decreased diameters, which was in direct proportion with the increase of nicotine concentrations. Based on these results, it is hypothesized that nicotine also has a role in the regulation of cellular cascades. It is possible that sensors of cytosolic mechanisms send signals to cell membrane proteins and to the nucleus, initiating mechanical events such as clustering and interactions between the cortical cell and skeletal structure.

In the present study, actin filaments were located at the region underneath the nuclear membrane. Actin filaments were also observed to increase around the inner part of the cell membrane. Thus, the accumulation of F-actin was evaluated, which was most likely related to the cellular motility. Thus, nicotine has an effect on cell motility and associates with the metastatic process.

In the present study, as a result of administration of varying concentrations of nicotine to MCF-7 breast cancer cells, morphological changes occurred in the structure of the cytoskeleton and, at the same time, cells experienced stress depending on the concentration of nicotine. A previous study demonstrated that one of the most important obstacles in chemotherapy is the resistance that cancer cells develop against apoptosis (44). One of the current approaches in this context is to use various drugs along with anticancer medications in order to ensure sensitivity of cancer cells for chemotherapy and to break the resistance (45). Sak (44) identified that this resistance is developed in cancer patients who do not cease smoking and continue their exposure to nicotine. The results of a doxorubicin experiment, which was performed because nicotine-administered MCF-7 cells
had an increased number of stem cells and these cells were resistant to chemotherapy, it was demonstrated that MCF-7 breast cancer cells developed resistance against this chemotherapeutic agent (44).

To evaluate whether nicotine increases metastatic potential in breast cancer, lamellipodia formation on F-actin was investigated using TEM and fluorescence microscopy. In light of these parameters, the present findings regarding mobilization were confirmed by SEM and fluorescence microscopy. Although these results are considered to be associated with metastasis, they may provide a basis for further studies on cancer development.

It is necessary to determine molecular and genetic targets that would be helpful in destroying CSCs without damaging normal cells, and to detect genetic and epigenetic events that trigger cancer. To the best of our knowledge, no previous studies have been conducted on the effect of nicotine on drug resistance. Inhibition of signal pathways that are involved in the resistance mechanism of CSCs would create novel treatment possibilities and therefore further studies on signal pathways are required. In order for gene sequence analyses and molecular markers that inhibit or control the interaction of cells with nicotine to be realized in the near future, studies addressing the genetic and molecular basis of nicotine effects are required.

Resistance against doxorubicin may be explained by an increased number of CSCs due to the presence of nicotine. However, some transcriptional factors that may modulate resistance to doxorubicin may be responsible, which was based on the present result that no correlation was identified between the resistance against doxorubicin and the elevation of the stem cell-induced cancer.

In the present study, it was identified that the population of CSCs increased in the presence of nicotine in MCF-7 cells. Nicotine was also indicated to increase the proliferation of MCF-7 breast cancer cells and actin filaments. The present results have aided in the understanding of drug resistance in breast cancer cells.

In conclusion, it is believed that nicotine, which is effective in the occurrence of breast cancer, is also one of the factors that has a role in the development and metastasis of this cancer. The results of the present study suggested that smoking and other forms of long-term nicotine intake, such as through nicotine guns, electronic cigarettes and nicotine pastilles, which are used as aids for smoking cessation during the cancer process, also contribute to the mobilization of cancer cells and affect the progression and relapse of the disease.

Acknowledgements

The present study was supported by the Scientific Research Projects Coordination Unit of Istanbul University (project no. 25945).

References

1. Gonzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22, 2007.
2. Quail DF and Joyce JA: Microenvironmental regulation of tumor progression and metastasis. Nat Med 19: 1423-1437, 2013.
3. De Laurentiis A, Pardo OE, Palamidessi A, Jackson SP, Schoenwaelder SM, Reichmann E, Scita G and Arcaro A: The catalytic class I(a) P38K isoforms play divergent roles in breast cancer cell migration. Cell Signal 23: 529-541, 2011.
4. Bailly C, topoisomerase I poisons and suppressors as anticancer drugs. Curr Med Chem 7: 39-58, 2000.
5. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N and Sarkar S: Drug resistance in cancer: An overview. Cancers (Basel) 6: 1769-1792, 2014.
6. Saimet JM, Avila-Tang E, Boffetta P, Hannan LM, Olivo-Marston S, Than MJ and Rudin CH: Lung cancer in never smokers: Clinical epidemiology and environmental risk factors. Clin Cancer Res 15: 5626-5645, 2009.
7. Cancer among adults from exposure to secondhand smoke, The health consequences of involuntary exposure to tobacco smoke: A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention (US), 2006.
8. Benowitz NL: Biomarkers of Cigarette Smoking. In: Monograph 7: The FTC Cigarette Test Method for Determining Tar, Nicotine, and Carbon Monoxide Yields of U.S. Cigarettes. National Cancer Institute, Bethesda, MD, pp93-111, 1988.
9. Centers for Disease Control and Prevention (US): National Center for Chronic Disease Prevention and Health Promotion (US); Office on Smoking and Health (US): Nicotine Addiction: Past and Present. In: How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta, GA, 2010.
10. Dani JA and De Biasi M: Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 70: 439-446, 2001.
11. Clark CA, McEachern MD, Shah SH, Rong Y, Rong X, Smalley ER, Caldito GC, Abreo FW and Nathan CO: Nicotine inhibits carcinogen and nicotine-induced malignant target of Rapamycin pathway activation in head and neck squamous cell carcinoma. Cancer Prev Res (Phila) 3: 1586-1595, 2010.
12. Schaal C and Chellappan SP: Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers. Mol Cancer Res 12: 14-23, 2014.
13. Heeschen C, Jang JJ, Weis M, Pathak A, Kaji S, Hu RS, Tsao PS, Johnson FL and Cooke JP: Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 7: 833-839, 2001.
14. Petros WP, Younis IR, Ford JD and Weed SA: Effects of tobacco smoking and nicotine on cancer treatment. Pharmacotherapy 32: 920-931, 2012.
15. Singh S, Pillai S and Chellappan S: Nicotinic acetylcholine receptor signaling in tumor growth and metastasis. J Oncol 2011: 135039.
16. Suraneni MV and Badeaux MD: Tumor-Initiating cells, cancer metastasis and therapeutic implications, madame curie bioscience database. In: Madame Curie Bioscience Database [Internet]. Landes Bioscience, Austin, TX, 2013.
17. Davis R, Rizwani W, Banerjee S, Kovacs M, Haura E, Coppola D and Chellappan S: Nicotine promotes tumor growth and metastasis in mouse models of lung cancer. PLoS One 4: e7824, 2009.
18. Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruyberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A and Hegardt C: The CD44+/CD24− phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10: R53, 2008.
19. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988, 2003.
20. Lorico A and Rappa G: Phenotypic heterogeneity of breast cancer stem cells. J Oncol 2011: 135039.
21. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J and Song E: TCF-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123, 2007.
22. De Laurentiis M, Cianiello D, Caputo R, Stanzione B, Arpino G, Cinieri S, Lorusso V and De Placido S: Treatment of triple negative breast cancer (TNBC): Current options and future perspectives. Cancer Treat Rev 36 (Suppl 3), S80-S86, 2010.
23. Muñoz-Pinedo C, El Mjiyad N and Ricci JE: Cancer metabolism: Current perspectives and future directions. Cell Death Dis 3: e248, 2012.
24. Rivera E and Gomez H: Chemotherapy resistance in metastatic breast cancer: The evolving role of ixabepilone. Breast Cancer Res 12 (Suppl 2): S2, 2010.
25. Park SY, Lee HE, Li H, Shipitsin M, Gelman R and Polyak K: Heterogeneity for stemcell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 16: 876-887, 2010.

26. Hussain F and Nguyen QT: Molecular imaging for cancer diagnosis and surgery. Adv Drug Deliv Rev 66: 90-100, 2014.

27. Groebel K, Hoelzle K, Wittenbrink MM, Ziegler U and Hoelzle LE: Mycoplasma suis invades porcine erythrocytes. Infect Immun 77: 576-584, 2009.

28. Varol B, Bektaş M, Nurten R and Bermek E: The cytotoxic effect of diphtheria toxin on the actin cytoskeleton. Cell Mol Biol Lett 17: 49-61, 2012.

29. Mitchell RR, Szabo E, Benoit YD, Case DT, Mechael R, Alamilla J, Lee HJ, Fiebig-Comyn A, Gillespie DC and Bhatia M: Activation of neural cell fate programs toward direct conversion of adult human fibroblasts into tri-potent neural progenitors using OCT-4. Stem Cells Dev 23: 1937-1947, 2014.

30. Jensen K, Afroze S, Munshi MK, Guerrier M and Glaser SS: Mechanisms for nicotine in the development and progression of gastrointestinal cancers. Transl Gastrointest Cancer 1: 81-87, 2012.

31. Karamboulas C and Ailles L: Developmental signaling pathways in cancer stem cells of solid tumors. Biochim Biophys Acta 1830: 2481-2495, 2013.

32. Pereira ML, Carvalho JC, Peres F, Gutierres M and Fernandes MH: Behaviour of human osteoblastic cells cultured on plasma-sprayed titanium implants in the presence of nicotine. Clin Oral Implants Res 19: 582-589, 2008.

33. Berger MR and Zeller WJ: Interaction of nicotine with anticancer treatment. Klin Wochenschr 66 (Suppl 11): S127-S133, 1988.

34. Benowitz NL, Hukkanen J and Jacob P III: Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol: 29-60, 2009.

35. Hukkanen J, Jacob P III and Benowitz NL: Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57: 79-115, 2005.

36. Russell MA, Feyerabend C and Cole PV: Plasma nicotine levels after cigarette smoking and chewing nicotine gum. Br Med J 1: 1043-1046, 1976.

37. Sobus SL and Warren GW: The biologic effects of cigarette smoke on cancer cells. Cancer 120: 3617-2627, 2014.

38. Warren GW and Singh AK: Nicotine and lung cancer. J Carcinog 12: 1, 2013.

39. Wei W and Lewis MT: Identifying and targeting tumor-initiating cells in the treatment of breast cancer. Endoec Relat Cancer 22: R135-R155, 2015.

40. Murin S and Inchiardi J: Cigarette smoking and the risk of pulmonary metastasis from breast cancer. Chest 119: 1635-1640, 2001.

41. Pomorski P, Wasik A, Kolodziejczyk J, GréBeck L and Kłopocka W: Nicotine affects behaviour, morphology and cortical cytoskeleton of amoeba proteus. Acta Protozool 43: 193-198, 2004.

42. Krause RM, Buisson B, Bertrand S, Corringer PJ, Galzi JL, Changeux JP and Bertrand D: Ivermectin: A possible allosteric effector of the alpha 7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 53: 283-294, 1998.

43. Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284, 2005.

44. Sak K: Chemotherapy and dietary phytochemical agents. Chemother Res Pract 2012: 282570, 2012.

45. You HB and Park K: Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release 153: 198-205, 2011.